1. Home
  2. ARDX vs GERN Comparison

ARDX vs GERN Comparison

Compare ARDX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$3.42

Market Cap

975.9M

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.29

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARDX
GERN
Founded
2007
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
975.9M
1.0B
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
ARDX
GERN
Price
$3.42
$1.29
Analyst Decision
Strong Buy
Hold
Analyst Count
7
3
Target Price
$15.14
$2.17
AVG Volume (30 Days)
3.9M
8.7M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.85
EPS
N/A
N/A
Revenue
$2,607,000.00
$1,065,000.00
Revenue This Year
$37.75
$26.91
Revenue Next Year
$34.24
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$1.04
52 Week High
$8.40
$2.01

Technical Indicators

Market Signals
Indicator
ARDX
GERN
Relative Strength Index (RSI) 24.11 38.92
Support Level N/A $1.24
Resistance Level $3.92 $1.32
Average True Range (ATR) 0.12 0.07
MACD 0.01 -0.02
Stochastic Oscillator 14.53 11.43

Price Performance

Historical Comparison
ARDX
GERN

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: